OCS
Oculis Holding AG (OCS)
Healthcare • NASDAQ • $32.64+4.99%
- Symbol
- OCS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $32.64
- Daily Change
- +4.99%
- Market Cap
- $1.89B
- Trailing P/E
- N/A
- Forward P/E
- -15.04
- 52W High
- $32.76
- 52W Low
- $16.00
- Analyst Target
- $48.10
- Dividend Yield
- N/A
- Beta
- 0.20
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was fo…
Company websiteResearch OCS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.